Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.5 - $5.23 $13,950 - $16,213
-3,100 Reduced 33.7%
6,100 $31,000
Q1 2024

May 15, 2024

SELL
$4.9 - $6.91 $2,450 - $3,455
-500 Reduced 5.15%
9,200 $45,000
Q4 2023

Feb 14, 2024

BUY
$4.56 - $6.59 $23,255 - $33,609
5,100 Added 110.87%
9,700 $54,000
Q3 2023

Nov 14, 2023

SELL
$5.2 - $7.32 $390,000 - $549,000
-75,000 Reduced 94.22%
4,600 $28,000
Q2 2023

Aug 14, 2023

BUY
$4.11 - $6.81 $293,043 - $485,553
71,300 Added 859.04%
79,600 $507,000
Q1 2023

May 15, 2023

BUY
$4.0 - $4.67 $11,200 - $13,076
2,800 Added 50.91%
8,300 $33,000
Q4 2022

Feb 14, 2023

SELL
$3.75 - $7.69 $58,875 - $120,733
-15,700 Reduced 74.06%
5,500 $24,000
Q3 2022

Nov 14, 2022

BUY
$7.21 - $9.47 $152,852 - $200,764
21,200 New
21,200 $159,000

Others Institutions Holding CSBR

About CHAMPIONS ONCOLOGY, INC.


  • Ticker CSBR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 13,522,400
  • Market Cap $57.6M
  • Description
  • Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Techn...
More about CSBR
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.